Literature DB >> 11166623

p53 immunoreactivity correlates with Ki-67 and bcl-2 expression in renal cell carcinoma.

A F. Olumi1, N Weidner, J C. Presti.   

Abstract

This study assessed the relation of proliferation, inhibition of apoptosis, and the p53 tumor suppressor protein expression in clear renal cell carcinoma (RCC). Archival pathological specimens from 43 patients treated for RCC were obtained. Median follow-up for the patients was 52 months (range 2.5 months to 178 months). Immunostaining of paraffin tissue sections was carried out for four different markers: a) Ki-67, a marker for cellular proliferation; b) p53/DO7, c) p53/pAb240, antibodies for the p53 protein; and d) bcl-2, a marker for inhibition of apoptosis (programmed cell death). One thousand cells were counted per slide at 400x magnification. Staining of >/=10% of cells was considered positive and <10% negative. Fisher exact contingency tables were used for correlation between markers, tumor grade and stage. A significant correlation was found between Ki-67 and p53 immunoreactivity samples, P=0.0001. Interestingly, a significant association was found if Ki-67 and bcl-2 scores were combined and correlated with p53, P=0.009. Results showed no correlation between any of the immunohistochemical markers and grade or stage. In addition, Kaplan-Meier survival curves demonstrated no significant difference between patients' tumors that was scored immunoreactive negative vs. positive for Ki-67, p53, or bcl-2. This study indicates that p53 expression correlates with proliferation, and inhibition of programmed cell death in RCC.

Entities:  

Year:  2001        PMID: 11166623     DOI: 10.1016/s1078-1439(00)00109-5

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  7 in total

Review 1.  p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?

Authors:  Aidan P Noon; Nikolina Vlatković; Radosław Polański; Maria Maguire; Howida Shawki; Keith Parsons; Mark T Boyd
Journal:  Cancer       Date:  2010-02-15       Impact factor: 6.860

2.  Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis.

Authors:  Zhun Wang; Shuanghe Peng; Ning Jiang; Aixiang Wang; Shuguang Liu; Hui Xie; Linpei Guo; Qiliang Cai; Yuanjie Niu
Journal:  Oncotarget       Date:  2017-10-19

3.  Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma.

Authors:  Tastekin Ebru; Oz Puyan Fulya; Akdere Hakan; Yurut-Caloglu Vuslat; Sut Necdet; Can Nuray; Ozyilmaz Filiz
Journal:  Int Braz J Urol       Date:  2017 May-Jun       Impact factor: 1.541

4.  Epstein-Barr virus infection is associated with the nuclear factor-kappa B p65 signaling pathway in renal cell carcinoma.

Authors:  Ali Farhadi; Sepide Namdari; Pei Pei Chong; Bita Geramizadeh; Abbas Behzad-Behbahani; Zamberi Sekawi; Sedigheh Sharifzadeh
Journal:  BMC Urol       Date:  2022-02-07       Impact factor: 2.264

5.  Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals.

Authors:  Zhun Wang; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Cancer Manag Res       Date:  2017-11-21       Impact factor: 3.989

6.  MicroRNA-34a: A Key Regulator in the Hallmarks of Renal Cell Carcinoma.

Authors:  Eman A Toraih; Afaf T Ibrahiem; Manal S Fawzy; Mohammad H Hussein; Saeed Awad M Al-Qahtani; Aly A M Shaalan
Journal:  Oxid Med Cell Longev       Date:  2017-09-20       Impact factor: 6.543

7.  Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.

Authors:  Tian Zhang; Sarabjot Pabla; Felicia L Lenzo; Jeffrey M Conroy; Mary K Nesline; Sean T Glenn; Antonios Papanicolau-Sengos; Blake Burgher; Vincent Giamo; Jonathan Andreas; Yirong Wang; Wiam Bshara; Katherine G Madden; Keisuke Shirai; Konstantin Dragnev; Laura J Tafe; Rajan Gupta; Jason Zhu; Matthew Labriola; Shannon McCall; Daniel J George; Pooja Ghatalia; Farshid Dayyani; Robert Edwards; Michelle S Park; Rajbir Singh; Robin Jacob; Saby George; Bo Xu; Matthew Zibelman; Razelle Kurzrock; Carl Morrison
Journal:  Oncoimmunology       Date:  2020-06-10       Impact factor: 8.110

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.